LANTERN PHARMA INC
NASDAQ: LTRN (Lantern Pharma Inc.)
Kemas kini terakhir: 12 jam lalu1.12
-0.97 (-46.41%)
| Penutupan Terdahulu | 2.09 |
| Buka | 2.23 |
| Jumlah Dagangan | 7,369,131 |
| Purata Dagangan (3B) | 52,889 |
| Modal Pasaran | 12,526,554 |
| Harga / Buku (P/B) | 3.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Mar 2026 |
| EPS Cair (TTM) | -1.84 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.16% |
| Nisbah Semasa (MRQ) | 4.86 |
| Aliran Tunai Operasi (OCF TTM) | -19.12 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.95 M |
| Pulangan Atas Aset (ROA TTM) | -43.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Lantern Pharma Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.63 |
|
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group’s growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.10% |
| % Dimiliki oleh Institusi | 21.12% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bios Capital Management, Lp | 31 Dec 2025 | 1,009,507 |
| Voss Capital, Lp | 31 Dec 2025 | 50,000 |
| Newedge Advisors, Llc | 31 Dec 2025 | 38,069 |
| Westside Investment Management, Inc. | 31 Dec 2025 | 35,900 |
| Horizon Kinetics Asset Management Llc | 31 Dec 2025 | 27,582 |
| Davenport & Co Llc | 31 Dec 2025 | 23,814 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Jan 2026 | Pengumuman | Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas |
| 12 Jan 2026 | Pengumuman | Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |